



옵티팜
OPTIPHARM

2018년 양계 질병 세균 항생제 내성 검사 결과

I Seul Oh

ACE of Optipharm

ois@optipharm.co.kr

043-249-7532

Contents

- I. 항생제 내성/감수성 기준 및 용어 설명
- II. 양계 질병 3종 항생제 내성 검사 결과

1. 항생제 감수성/ 내성 기준

항생제 감수성/ 내성 기준

• 항생제 종류 및 기준(디스크 확산법 기준으로 검역원 자료 참조)

약제명	감수성	효과 중간	내성	약제명	감수성	효과 중간	내성
Ampicillin(AMP10)	17	14	6	Gentamicin(CN10)	15	13	6
Amoxicillin(AML30)	18	14	6	Linsmycin(LS109)	17	13	6
Bacitracin(B10)	12	8	6	Neomycin(N30)	17	13	6
Erythromycin(E30)	23	14	6	Apramycin(APR15)	17	13	6
Tilmicosin(TIL15)	11		10	Tiamulin H.Fumarate(Ti25)	17	13	6
Colistin(CT10)	11		10	Streptomycin(S10)	15	12	6
Enrofloxacin(ENR5)	23	17	6	Tetracycline(T30)	15	12	6
Florfenicol(FFC25)	22	19	6	Trimethoprim/ Sulfamethoxazole(STX25)	18	15	6
Ceftiofur sodium(C2.5)	21	18	6	Tylosin tartrate(Ty25)	18	13	6

• 항생제 종류 및 기준


Sensitive(감수성)	감수성이 있다는 의미로 치료 효과를 기대할 수 있음.
Resistant(내성)	내성이 있다는 의미로 치료효과 없음.
Intermediate(효과 중간)	감수성과 내성의 중간 정도.

2. 양계 세균성 질병 3종


Salmonella spp.

약 제 명	농장수	검사횟수	항생제 내성, 효과중간, 감수성 비율					
			Resistant		Intermediate		Sensitive	
			검출횟수	%	검출횟수	%	검출횟수	%
Ampicillin(AMP10)	16	29	4	13.8%	6	20.7%	19	65.5%
Amoxicillin(AML30)			5	17.2%	0	0.0%	24	82.8%
Bacitracin(B10)			29	100.0%	0	0.0%	0	0.0%
Erythromycin(E30)			29	100.0%	0	0.0%	0	0.0%
Tilmicosin(TIL15)			28	96.6%	0	0.0%	1	3.4%
Colistin(CT10)			1	3.4%	0	0.0%	28	96.6%
Enrofloxacin(ENR5)			9	31.0%	17	58.6%	3	10.3%
Florfenicol(FFC25)			16	55.2%	5	17.2%	8	27.6%
Ceftiofur sodium(C2.5)			FALSE	0.0%	12	41.4%	13	44.8%
Gentamycin(CN10)			14	48.3%	9	31.0%	6	20.7%
Linsmycin(LS109)			22	75.9%	3	10.3%	4	13.8%
Neomycin(N30)			0	0.0%	1	3.4%	28	96.6%
Apramycin(APR15)			1	3.4%	3	10.3%	25	86.2%
Tiamulin H.Fumarate(Ti25)			28	96.6%	1	3.4%	0	0.0%
Streptomycin(S10)			28	96.6%	0	0.0%	1	3.4%
Tetracycline(T30)			3	10.3%	0	0.0%	26	89.7%
Trimethoprim/ Sulfamethoxazole(STX25)	16	55.2%	7	24.1%	6	20.7%		
Tylosin tartrate(Ty25)	29	100.0%	0	0.0%	0	0.0%		

Salmonella spp.




Salmonella spp.




Escherichia coli

약 제 명	농장수	검사횟수	항생제 내성, 효과중간, 감수성 비율					
			Resistant		Intermediate		Sensitive	
			검출횟수	%	검출횟수	%	검출횟수	%
Ampicillin(AMP10)	15	29	17	58.6%	8	27.6%	4	13.8%
Amoxicillin(AML30)			17	58.6%	1	3.4%	11	37.9%
Bacitracin(B10)			29	100.0%	0	0.0%	0	0.0%
Erythromycin(E30)			28	96.6%	1	3.4%	0	0.0%
Tilmicosin(TIL15)			26	89.7%	0	0.0%	3	10.3%
Colistin(CT10)			0	0.0%	0	0.0%	29	100.0%
Enrofloxacin(ENR5)			23	79.3%	5	17.2%	1	3.4%
Florphenicol(FFC25)			18	62.1%	11	37.9%	0	0.0%
Ceftiofur sodium(C2.5)			5	17.2%	9	31.0%	15	51.7%
Gentamycin(CN10)			6	20.7%	2	6.9%	21	72.4%
Linsmycin(LS109)			4	13.8%	13	44.8%	12	41.4%
Neomycin(N30)			3	10.3%	13	44.8%	13	44.8%
Apramycin(APR15)			6	20.7%	22	75.9%	1	3.4%
Tiamulin H.Fumarate(Ti25)			25	86.2%	3	10.3%	1	3.4%
Streptomycin(S10)			16	55.2%	12	41.4%	1	3.4%
Tetracycline(T30)			17	58.6%	0	0.0%	12	41.4%
Trimethoprim/ Sulfamethoxazole(STX25)			12	41.4%	2	6.9%	15	51.7%
Tylosin tartrate(Ty25)			29	100.0%	0	0.0%	0	0.0%

Escherichia coli




Escherichia coli




Clostridium perfringens

약 제 명	농장수	검사횟수	항생제 내성, 효과중간, 감수성 비율					
			Resistant		Intermediate		Sensitive	
			검출횟수	%	검출횟수	%	검출횟수	%
Ampicillin(AMP10)	4	6	0	0.0%	0	0.0%	6	100.0%
Amoxicillin(AML30)			0	0.0%	0	0.0%	6	100.0%
Bacitracin(B10)			0	0.0%	0	0.0%	6	100.0%
Erythromycin(E30)			3	50.0%	3	50.0%	0	0.0%
Tilmicosin(TIL15)			0	0.0%	0	0.0%	6	100.0%
Colistin(CT10)			6	100.0%	0	0.0%	0	0.0%
Enrofloxacin(ENR5)			0	0.0%	4	66.7%	2	33.3%
Florfenicol(FFC25)			0	0.0%	3	50.0%	3	50.0%
Ceftiofur sodium(C2.5)			2	33.3%	1	16.7%	3	50.0%
Gentamycin(CN10)			6	100.0%	0	0.0%	0	0.0%
Linsmycin(LS109)			2	33.3%	2	33.3%	2	33.3%
Neomycin(N30)			6	100.0%	0	0.0%	0	0.0%
Apramycin(APR15)			6	100.0%	0	0.0%	0	0.0%
Tiamulin H.Fumarate(Ti25)			0	0.0%	0	0.0%	6	100.0%
Streptomycin(S10)			6	100.0%	0	0.0%	0	0.0%
Tetracycline(T30)			0	0.0%	0	0.0%	6	100.0%
Trimethoprim/ Sulfamethoxazole(STX25)			5	83.3%	1	16.7%	0	0.0%
Tylosin tartrate(Ty25)			0	0.0%	0	0.0%	6	100.0%

Clostridium perfringens



Clostridium perfringens



■ Resistant ■ Intermediate ■ Sensitive